Literature DB >> 10660329

Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.

V M De Benedetti1, P Radice, B Pasini, L Stagi, V Pensotti, P Mondini, S Manoukian, A Conti, G Spatti, F Rilke, M A Pierotti.   

Abstract

Germline mutations in the BRCA1 and BRCA2 genes are associated with approximately 80% of families with a high incidence of breast and/or ovarian cancers (OMIM database reference numbers: 113705, 600185). Furthermore, constitutional mutations in the these genes have been reported in women with early-onset breast carcinoma and without family history of cancer. We analyzed by protein truncation test (PTT) and single strand conformation polymorphism (SSCP) followed by sequence analysis, BRCA1 exons 11 and 20 and BRCA2 exons 10 and 11 in 142 Italian cancer patients. These included six male breast cancer cases, 61 women with breast carcinoma diagnosed before 36 years old and selected independently of family history of breast cancer and 75 familial breast and/or ovarian cancer patients. In a previous report, we described 11 different BRCA1 mutations in a subset of 70 cases. Here, we report the characterization of 23 additional mutations, 14 in BRCA1 and 9 in BRCA2, subsequently identified. Ten mutations were not previously described, while the other 13 were recurrent. Of the 61 women with early-onset breast cancer, 11 carried a germline mutation in BRCA1 (18.0%) and four in BRCA2 (6.6%). These frequencies indicate that BRCA1/BRCA2 genetic tests should be advised to women with breast cancer diagnosed at early age, independently of family history of cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10660329

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  5 in total

1.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

2.  BRCA1 and BRCA2 mutations in central and southern Italian patients.

Authors:  L Ottini; C D'Amico; C Noviello; S Lauro; M Lalle; G Fornarini; O A Colantuoni; C Pizzi; E Cortesi; S Carlini; F Guadagni; A R Bianco; L Frati; A Contegiacomo; R Mariani-Costantini
Journal:  Breast Cancer Res       Date:  2000-03-31       Impact factor: 6.466

3.  Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

Authors:  Rumyana Ivanova Dodova; Atanaska Velichkova Mitkova; Daniela Rosenova Dacheva; Lina Basam Hadjo; Alexandrina Ivanova Vlahova; Margarita Stoyanova Taushanova -Hadjieva; Spartak Stoyanov Valev; Marija Mitko Caulevska; Stanislava Dimitrova Popova; Ivan Emilov Popov; Tihomir Iliichev Dikov; Theophil Angelov Sedloev; Atanas Stefanov Ionkov; Konstanta Velinova Timcheva; Svetlana Liubomirova Christova; Ivo Marinov Kremensky; Vanio Ivanov Mitev; Radka Petrova Kaneva
Journal:  BMC Cancer       Date:  2015-07-17       Impact factor: 4.430

4.  The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Luise D Resch; Alrun Hotz; Andreas D Zimmer; Katalin Komlosi; Nina Singh; Andreas Tzschach; Marisa Windfuhr-Blum; Ingolf Juhasz-Boess; Thalia Erbes; Judith Fischer; Svenja Alter
Journal:  Genes (Basel)       Date:  2021-09-24       Impact factor: 4.096

5.  Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Authors:  Mateja Krajc; Erik Teugels; Janez Zgajnar; Guido Goelen; Nikola Besic; Srdjan Novakovic; Marko Hocevar; Jacques De Grève
Journal:  BMC Med Genet       Date:  2008-09-10       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.